The current approach for managing such ocular surface disorders involves the use of non-preserved anti-glaucoma eye drops, as well as the addition of non-preserved artificial tears or lubricants, including hyaluronic acid eye drops or mucin secretagogues such as diquafosol sodium or rebamipide eye drops, into the treatment regimen. The gene discussed is MUC5AC; the disease is glaucoma.